|

Bendamustine Clinical Trials

27 actively recruiting trials across 16 locations

Also known as: Belrapzo®, Bendamustine hydrochloride, Bendeka, Bendeka, Treanda, Bendeka®, C16H21Cl2N3O2 · HCl, SDX-105, Treanda, Treanda®

Other9 trials

A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
Phase 3
A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
Phase 3
A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype
Phase 3
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
Phase 2
A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma
Phase 2
Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment
Phase 3
Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma
Phase 3
Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy
Phase 2

Gilbert, Arizona2 trials

DALY II USA/ MB-CART2019.1 for DLBCL

Banner MD Anderson Cancer Center

Phase 2
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

Banner MD Anderson Cancer Center

Phase 1

Chapel Hill, North Carolina2 trials

CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma

Lineberger Comprehensive Cancer Center at University of North Carolina

Phase 2
Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Lineberger Comprehensive Cancer Center at University of North Carolina

Phase 1

Birmingham, Alabama1 trial

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

Local Institution - 0225

Phase 3

Glendale, Arizona1 trial

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

Palo Verde Hematology/ Oncology Center, Ltd. ( Site 0175)

Phase 2/3

Phoenix, Arizona1 trial

BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma

Mayo Clinic Arizona

Phase 2

Scottsdale, Arizona1 trial

MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer

Mayo Clinic in Arizona

Phase 1

Jonesboro, Arkansas1 trial

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

St Bernards Medical Center

Phase 3

Berkeley, California1 trial

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

Alta Bates Summit Medical Center

Phase 3

Fresno, California1 trial

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

UCSF Fresno /ID# 264712

Phase 3

Fullerton, California1 trial

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

Providence Medical Foundation

Phase 1

Denver, Colorado1 trial

Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM

Colorado Blood Cancer Institute (CBCI)

Phase 2

Jacksonville, Florida1 trial

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

Mayo Clinic in Florida

Phase 1

Boston, Massachusetts1 trial

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

Boston Medical Center

Phase 1/2

Rochester, Minnesota1 trial

CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies

Mayo Clinic in Rochester

Phase 1

Houston, Texas1 trial

Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant

M D Anderson Cancer Center

Phase 1/2

Seattle, Washington1 trial

Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations

Fred Hutch/University of Washington Cancer Consortium

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.